Zacks Research Upgrades Cerus (NASDAQ:CERS) to Hold

Cerus (NASDAQ:CERS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

A number of other brokerages have also recently commented on CERS. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Friday. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a report on Wednesday, March 25th. Finally, TD Cowen reiterated a “buy” rating on shares of Cerus in a report on Monday, January 12th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cerus has a consensus rating of “Hold” and an average target price of $4.00.

Cerus Trading Up 34.0%

Shares of CERS stock traded up $0.69 on Thursday, reaching $2.72. The company had a trading volume of 24,789,625 shares, compared to its average volume of 970,124. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The stock has a market cap of $545.01 million, a PE ratio of -34.00 and a beta of 1.62. The company has a 50-day moving average of $1.97 and a 200-day moving average of $1.98. Cerus has a 12 month low of $1.15 and a 12 month high of $3.15.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $59.89 million during the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative return on equity of 15.63% and a negative net margin of 4.41%. On average, equities analysts forecast that Cerus will post -0.05 earnings per share for the current year.

Insiders Place Their Bets

In other Cerus news, CEO William Mariner Greenman sold 447,757 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total transaction of $743,276.62. Following the transaction, the chief executive officer owned 4,998,493 shares of the company’s stock, valued at $8,297,498.38. The trade was a 8.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Vivek K. Jayaraman sold 165,200 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $274,232.00. Following the transaction, the chief operating officer directly owned 1,747,674 shares in the company, valued at $2,901,138.84. This trade represents a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,194,282 shares of company stock valued at $2,106,290 over the last 90 days. 5.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Cibc World Markets Corp acquired a new position in shares of Cerus during the 4th quarter worth approximately $25,000. CIBC Bancorp USA Inc. acquired a new position in shares of Cerus during the 3rd quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Cerus during the 1st quarter worth approximately $32,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Cerus during the 1st quarter worth approximately $35,000. Finally, Aquatic Capital Management LLC acquired a new position in shares of Cerus during the 3rd quarter worth approximately $35,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations: revenue rose ~22.6% YoY to $59.9M and diluted EPS was -$0.01, beating estimates — the top?line beat and narrower loss are being cited as the primary catalyst lifting the stock. QuiverQuant: Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research raised CERS from “neutral” to “buy” with a $4.00 price target (material upside to the current level), which can attract momentum buyers and fresh coverage. The Fly / BTIG upgrade
• Positive Sentiment: Improving profitability & cash flow: operating loss narrowed substantially vs. last year, net loss fell sharply, and operating cash flow was positive ($6.2M); these trends reduce near?term funding pressure. QuiverQuant: financial details
• Neutral Sentiment: Detailed context is available in the earnings call/transcripts for investors who want management color on growth drivers and timing. Seeking Alpha Transcript
• Neutral Sentiment: Small government contract receipts and mixed institutional flows: some large funds added positions while others reduced holdings — signals of both conviction and rotation into/out of the name. QuiverQuant: institutional & contract data
• Negative Sentiment: FY2026 revenue guidance was updated to $227.0M–$231.0M, which sits below consensus (~$233.9M) — the guide shortfall may cap upside if investors focus on FY outlook rather than the quarterly beat. MarketBeat: guidance note
• Negative Sentiment: Significant insider selling over recent months is a red flag for some investors and may weigh on sentiment despite improving results. QuiverQuant: insider trades

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.